Pfizer: CEO Bets His Pension On The Stock - Upgrading To Buy

Michael M. Santiago It's one thing to find a cheaply valued company and another thing to identify a lucrative investment opportunity. Pfizer Inc. (PFE) has been cheap for some time now, with the pharmaceutical giant suffering from lackluster growth in the post-pandemic era with the positive financial impact of Comirnaty and Paxlovid waning. Last November, I found Pfizer cheaply valued, but I failed to identify a catalyst that could drive PFE stock higher in the foreseeable future. In my previous article, af ...